Bharat Biotech ramps up COVAXIN production volumes by additional 200 million

Bharat Biotech announced the ramp-up of additional manufacturing capacities for COVAXIN at Chiron Behring Vaccines, Ankleshwar Gujarat, a wholly-owned subsidiary of Bharat Biotech.

The company plans to produce 200 million doses of COVAXIN per annum in GMP facilities that are already operational for the production of vaccines based on Inactivated Vero Cell Platform Technology. Product availability at Ankleshwar to commence from Q4 2021.

In a statement, the company informed, “Bharat Biotech had already deployed multiple production lines at its Hyderabad and Bengaluru campuses, adding Chiron Behring to this line up of high containment BSL rated GMP facilities that are required to manufacture COVAXIN. This effectively takes the volumes upto one billion doses per annum, with its own established campuses specialised for manufacturing inactivated viral vaccines under the highest levels of biosafety.”